These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36615205)

  • 1. Quality by Design Approach in Liposomal Formulations: Robust Product Development.
    Alshaer W; Nsairat H; Lafi Z; Hourani OM; Al-Kadash A; Esawi E; Alkilany AM
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-by-design-based engineered liposomal nanomedicines to treat cancer: an in-depth analysis.
    Kapoor D; Sharma S; Verma K; Bisht A; Sharma M; Singhai NJ; Raval N; Maheshwari R
    Nanomedicine (Lond); 2022 Jul; 17(17):1173-1189. PubMed ID: 36178357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of critical process parameters and critical material attributes on the critical quality attributes of liposomal formulations prepared using continuous processing.
    Yenduri G; Costa AP; Xu X; Burgess DJ
    Int J Pharm; 2022 May; 619():121700. PubMed ID: 35358645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.
    Rawal M; Singh A; Amiji MM
    Pharm Res; 2019 Sep; 36(11):153. PubMed ID: 31482243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
    Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
    Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach.
    Waghule T; Dabholkar N; Gorantla S; Rapalli VK; Saha RN; Singhvi G
    Biomed Pharmacother; 2021 Sep; 141():111940. PubMed ID: 34328089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal Drug Product Development and Quality: Current US Experience and Perspective.
    Kapoor M; Lee SL; Tyner KM
    AAPS J; 2017 May; 19(3):632-641. PubMed ID: 28160164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach.
    Tefas LR; Sylvester B; Tomuta I; Sesarman A; Licarete E; Banciu M; Porfire A
    Drug Des Devel Ther; 2017; 11():1605-1621. PubMed ID: 28579758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments.
    Wang Y; Grainger DW
    Adv Drug Deliv Rev; 2019; 151-152():56-71. PubMed ID: 30898571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment.
    Amasya G; Aksu B; Badilli U; Onay-Besikci A; Tarimci N
    Int J Pharm; 2019 May; 563():110-121. PubMed ID: 30935913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer Optimization of Biodegradable Nanoparticles Fabricated by Dispersion Polymerization.
    Akala EO; Adesina S; Ogunwuyi O
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010047. PubMed ID: 26703678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition.
    Moloney C; Roy Chaudhuri T; Spernyak JA; Straubinger RM; Brougham DF
    Acta Biomater; 2023 Mar; 158():611-624. PubMed ID: 36603732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality by Design: Concept to Applications.
    Swain S; Parhi R; Jena BR; Babu SM
    Curr Drug Discov Technol; 2019; 16(3):240-250. PubMed ID: 29521238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual Solvents in Nanomedicine and Lipid-Based Drug Delivery Systems: a Case Study to Better Understand Processes.
    Dikpati A; Mohammadi F; Greffard K; Quéant C; Arnaud P; Bastiat G; Rudkowska I; Bertrand N
    Pharm Res; 2020 Jul; 37(8):149. PubMed ID: 32681392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
    Shaji J; Menon I
    Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products.
    Troiano G; Nolan J; Parsons D; Van Geen Hoven C; Zale S
    AAPS J; 2016 Nov; 18(6):1354-1365. PubMed ID: 27631558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.